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To find clearheaded scientific perspective
on cannabis use through the prevailing
thick smokescreen requires recognizing
just what sort of smoke obscures our bet-
ter understanding. In the United States,
in large part, the smokescreen is made up
of culture war-charged political rhetoric
and obstructionism from those in posi-
tions of authority setting up a prejudi-
cial ideological framing for cannabis use.
National leaders throughout the twentieth
century have taken opportunities afforded
by high office or its pursuit to pub-
licly opine on the dangers of cannabis,
such as when then-Presidential candidate
Ronald Reagan famously stated in 1980
that “leading medical researchers are com-
ing to the conclusion that marijuana, pot,
grass, whatever you want to call it, is
probably the most dangerous drug in the
United States and we haven’t begun to
find out all of the ill-effects. But they are
permanent ill-effects. The loss of mem-
ory, for example Grass (1999).” Not only
is such rhetoric overly simplistic, it also
obscures and distorts pre-existing facts.
In this particular case, Reagan’s state-
ment obscures the fact that the American
Medical Association testified in 1937 on
record to Congress that, after nearly 100
years of professional experience inWestern
medical practice with over 2000 pre-
scribable marketed cannabis preparations
(Antique Cannabis Museum, 2012), prac-
titioners found that cannabis had an irre-
placeable therapeutic role as an aid in
the remembering of old and long-forgotten
memories in psychotherapy patients (U.S.
Congress, 1937). When in office, Reagan’s
first drug czar, Carlton Turner, blamed
cannabis use for young people’s involve-
ment in “anti-military, anti-nuclear power,
anti-big business, anti-authority demon-
strations” (Schlosser, 1997), all dissenting
positions toward government initiatives.
Such clear scapegoating rhetoric has roots
in the government’s racialized Reefer
Madness campaign of the 1930s which
linked cannabis use in Blacks, Latinos,
jazz musicians, and juvenile delinquents to
racial miscegenation and homicidal mania
(Helmer, 1975).
With such a long tradition of distorting
rhetoric emanating from leading political
authorities and being broadcast widely by
the mass media, it is apparent how politi-
cized cannabis use has become and how
scientific research and knowledge about its
use have been selectively highlighted and
skewed to support pre-determined politi-
cal objectives. These persistent distortions
and political evasions are the greatest con-
tributors to the smokescreen that obscures
collection and dissemination of accurate
evidence on cannabis use. The smoke-
screen is perpetuated because, as the saying
goes, in war, the first casualty is the truth.
Maintaining existing controversial policies
relegating cannabis to the status of con-
traband (such as, under US federal law:
zero-tolerance for use, a death penalty for
trafficking amounts greater than approxi-
mately 66 tons, and official denial of cur-
rently accepted medical use in treatment)
tends to be of a greater priority to govern-
mental bodies than collecting and collating
basic evidence regarding its use to inform
public policy and health.
What evidence is gathered is often
rejected or simply ignored if politically
inexpedient. Here are a few examples.
On occasion, political leaders are actually
caught attempting to make “backroom”
deals to ensure that a scientific commis-
sion’s findings on cannabis use will have
a predetermined outcome intended to
marginalize political enemies. Take, for
example, what was explicitly caught on
tape during Richard Nixon’s presidency. As
documented on declassified tape record-
ings from the White House Oval Office
on September 9, 1971, Nixon privately
told his appointed Commission chair, for-
mer Pennsylvania Governor Raymond
Shafer, that it was “terribly important”
the Commission, tasked by Congress with
helping to determine what level of risk
cannabis use should be understood to
constitute for the purposes of legal reg-
ulation, not come out with a report that
was “soft on marijuana.” Strategizing for
political expediency over factual review
and nuance, Nixon called for obfusca-
tion: “I think there’s a need to come
out with a report that is totally, uh, uh,
oblivious to some obvious, uh, differ-
ences between marijuana and other drugs,
other dangerous drugs. . . ” Nixon further
warned Shafer: “Keep your Commission
in line (CSDP, 2012).” Despite the
Commission’s recommendations to the
contrary, cannabis was nevertheless main-
tained in the most restrictive category
under federal law, Schedule I, where it
has remained alongside heroin for 42
years, officially deemed to be devoid
of medical utility, or safety. After a 14-
year-delayed evidentiary hearing on a
citizen-led cannabis-rescheduling petition
filed in 1972 which lasted for 2 years, a
Drug Enforcement Administration (DEA)
Administrative Law Judge (ALJ) ruled in
1988 that cannabis should be resched-
uled to Schedule II, with painkillers and
anesthetics such as morphine and cocaine
with currently accepted medical uses, and
that to not do so would be “unreasonable,
arbitrary, and capricious (SLDP, 2012).”
The presidentially-appointed head of DEA
rejected his own agency judge’s ruling and,
in 1994, a federal court finally denied
the petitioners’ appeal. An additional
citizen-petition to reschedule cannabis
filed in 2002 was rejected by the DEA after
9 years of delay and is presently under
appeal (ASA, 2012). In 2007, another
DEA ALJ ruled that it would be “in the
public interest” to have more than one
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licensed facility to produce research-grade
cannabis, and that a Plant and Soil
Sciences Professor petitioner who had
applied in 2001 for a production license
and been denied be granted one. This DEA
judge’s ruling, too, was rejected by the
DEA head in 2009 and is presently under
appeal (MAPS, 2012). The rejection had
the effect of allowing the federal govern-
ment’s hamstringing of scientific research
to continue, with cannabis clinical stud-
ies being approved at an unacceptably
slow pace, testing substandard-quality
material produced under a government-
backed private monopoly, and supplied
only after potential investigators have
waded through tremendous red tape,
if supplied at all. Meanwhile, over the
same timeframe, private pharmaceuti-
cal interests backed by highly-profitable
international corporate pharmaceutical
distributors have been granted license
by the DEA to import and test in large,
multicenter clinical trials in the US pro-
prietary whole plant cannabis extracts
made in company-owned cannabis pro-
duction greenhouses licensed by friendlier
governments (Aggarwal, 2010).
The persisting Schedule I classification
of cannabis that the federal govern-
ment maintains is itself a smokescreen
that is directly discordant with author-
itative, independent, medico-scientific
evidence-based assessments. Publishing
in the open-access scientific literature
housed in the U.S. National Institutes of
Health’s National Library of Medicine,
clinical investigators who oversaw seven
separate, government-authorized, gold-
standard design clinical trials of the safety
and efficacy of smoked and vaporized
inhaled cannabis for specific indications
conducted at University of California
medical centers over a 10 years period
from 2002–2012 involving over 300
human subjects reported in an article
entitled “Medical Marijuana: Clearing
Away the Smoke” that all trials inde-
pendently showed benefit. The authors
concluded that the Schedule I classification
of cannabis, based on the evidence col-
lected and reviewed, is “not tenable,” “not
accurate,” and one of the main “obstacles
to medical progress (Grant et al., 2012).”
This position is concordant with the anal-
yses and conclusions in evidence-based
positions papers and reports on cannabis
medical science from leading national
medical academies and specialty soci-
eties (National Research Council, 1999;
American College of Physicians, 2008;
American Medical Association, 2009).
To begin to clear such a thick and recal-
citrant smokescreen of political rhetoric
and interference surrounding cannabis use
requires that a massive gust of fresh air be
let into the room. This will help to spur
a fundamental perspectival reorientation
that will allow us to breathe freely, return
to first principles, and start evidence-
gathering from the beginning. An expe-
dient smokescreen clearing approach is a
historical and comparative ecological one
that focuses on the human-cannabis rela-
tionship on a species to species level. We
will come back to the theoretical outlines
of this approach; for now, consider its
results. While Cannabis sativa evolved in
the Central Asian-Himalayan region ∼36
million years ago (McPartland and Guy,
2004), it has spread to all regions of human
habitation due to the long-standing fond-
ness Homo sapiens have had for this semi-
domesticated botanical cultivar, evidenced
by the undisputed prehistoric archaeo-
logical record (Russo et al., 2008) and
ancient textual references (Hillig, 2005).
Cannabis’s very name belies its long-
standing relationship with humanity, as it
was pragmatically given the species name
“Sativa” in 1542 by German physician-
botanist Leonhart Fuchs, meaning “culti-
vated” or “useful” in Latin (Russo, 2007).
It grows easily in numerous climates as a
wild and hardy plant whose palmate fan
leaf ’s geometry is iconic. Uses of Cannabis
sativa include production of textiles, build-
ing material, canvas, rope, paper, and bio-
fuel using the cellulose and fiber of its
stalk; nutritive food, edible oil, and lotions
using its oil- and protein-rich seeds;
and, most pointedly, herbal medicines,
spiritual sacraments, and psychoactive
inebriants using its phytocannabinoid-
rich resin-producing flowers and leaves
which, when ingested after heating, have
robust, non-lethal, receptor-based effects
via the human endogenous cannabi-
noid, or endocannabinoid, signaling sys-
tem. Such effects pharmacologically are
properly termed “cannabinergic.” The
endocannabinoid system is an essential
biological signaling system that appeared
600 million years ago in life (Melamede,
2005) and plays a master-regulatory role in
many physiological functions that humans
may naturally wish to self-adjust, such as
mood, appetite, memory, inflammation,
muscle tone, pain perception, and stress
management, in addition to other more
subtle but equally validated functions such
as neuroprotection, bone growth, immu-
nity, tumor regulation, seizure threshold,
gastrointestinal motility, and intraocular
pressure, to name a few (Di Marzo, 2004;
Pacher et al., 2006; Vettor et al., 2008).
When gathering evidence to address
behavioral questions surrounding human
consumption and production of poten-
tially psychoactive cannabis preparations,
it is absolutely essential that this long, co-
evolutionary arc of human history with
this cannabinergic plant be appreciated in
order to understand underlying human
values, and desires that motivate cannabis
use and prevent smokescreen prejudices
from taking root. The main question is:
what sorts of relationships can humans
have with cannabis, aside from aberrant,
pathological, and addictive ones? And, as a
corollary to this question, when cannabis
is consumed in contemporary settings,
does it necessarily have to be as a scarce
consumerist commodity, or do other rela-
tional possibilities exist? By addressing
such questions, a richer understanding
of cannabis use can emerge and lessen
the chance that use patterns are improp-
erly understood as pathological or deviant,
when they may fact be perfectly nor-
mal and healthful. Certainly the caveat
that cultural controls and norms regarding
cannabis use that play an important public
health role may not translate to all social
groups must be acknowledged.
A broader understanding of the
human-cannabis relationship beyond the
dominating twentieth century American
and colonial prohibitionist sociolegal
frameworks is needed. When there is not
a war against cannabis being fought, a less
distorted picture of its effects can emerge.
The element of psychological distress that
cannabis prohibition regimes produce is
worth seriously accounting for as it can
play a significant role in the conflation
of the effect of cannabis on a user with
the effect of the criminal or social stigma
attached to that use (Aggarwal et al., 2012).
A research approach from social science
known as political ecology, taken from
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anthropology and geography, which is
able to incorporate into its analysis the
total human-plant relationship and the
effects of local and global sociopolitical
forces, is helpful here (Robbins, 2004).
Political ecology is framework used to
study human-environment relations that
joins cultural ecology with political econ-
omy. Cultural ecology studies how cultural
groups adapt, adjust, and relate to their
natural environments, and political econ-
omy studies how political institutions, the
political environment, and economic sys-
tems influence each other (Mayer, 1996;
Johnston et al., 2007). A sampling of the
results of applying such an approach to
demystify the smokescreen was given
above.
By applying political ecology to
cannabis use and production, we can
begin to understand and appreciate tra-
ditional ecological knowledge regarding
its use and production, extant and extinct
cultural practices surrounding cannabis
use, and the history of their marginaliza-
tion.Western delegates first heard officially
from other countries who wished not to
impose absolute prohibition at United
Nations meetings in the early 1960s when
the first comprehensive international
treaty that would call for strict controls
on cannabis was being negotiated. Indeed,
while a number of thriving civilizations
have found a way to integrate cannabis
use into their legally sanctioned cultural
fabrics, such alternate sociocultural and
political realities were ultimately targeted
for suppression.
Substantial evidence has been gath-
ered regarding the efficacious use of
cannabis as a medicine to treat spe-
cific conditions. Additionally, convincing
evidence regarding the use of cannabis
as a non-problematic “recreational” psy-
choactive substance with a low poten-
tial for addiction has been collected and
become increasingly accepted in the US
and abroad. Public policy regimes recog-
nizing such use patterns—medical mar-
ijuana and adult marijuana use—have
taken root in several US states and inter-
nationally. However, two human-cannabis
use relationships, oft-neglected in medical
and public health literature, but for which
substantial evidence exists are cannabis use
as a spiritual or religious activity and as
an herbal or dietary supplement. These use
patterns were presented by international
delegates from countries such as India and
Pakistan for respectful consideration at
the UN but simply ignored and censured
(United Nations, 1961; Times of India,
2012). I call for more research and docu-
mentation on these use patterns globally
using the research framework described to
fully eradicate the smokescreen and see
clearly what exists.
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